دورية أكاديمية
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
| العنوان: | Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. |
|---|---|
| المؤلفون: | Paiva, Bruno, Puig, Noemi, Cedena, Maria-Teresa, Rosiñol, Laura, Cordón, Lourdes, Vidriales, María-Belén, Burgos, Leire, Flores-Montero, Juan, Sanoja-Flores, Luzalba, Lopez-Anglada, Lucia, Maldonado, Roberto, de la Cruz, Javier, Gutierrez, Norma C, Calasanz, Maria-Jose, Martin-Ramos, Maria-Luisa, Garcia-Sanz, Ramón, Martinez-Lopez, Joaquin, Oriol, Albert, Blanchard, María-Jesús, Rios, Rafael, Martin, Jesus, Martinez-Martinez, Rafael, Sureda, Anna, Hernandez, Miguel-Teodoro, de la Rubia, Javier, Krsnik, Isabel, Moraleda, Jose-Maria, Palomera, Luis, Bargay, Joan, Van Dongen, Jacques J M, Orfao, Alberto, Mateos, Maria-Victoria, Blade, Joan, San-Miguel, Jesús F, Lahuerta, Juan-José, GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group |
| سنة النشر: | 2019 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Clinical Trials, Phase III as Topic, Dexamethasone, Female, Flow Cytometry, Humans, Lenalidomide, Longitudinal Studies, Male, Middle Aged, Multiple Myeloma, Neoplasm, Residual, Randomized Controlled Trials as Topic |
| الوصف: | Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1,100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 × 10-6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial. Overall, 205 (45%) of 458 patients had undetectable MRD after consolidation, and only 14 of them (7%) have experienced progression thus far; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse. Using time-dependent analysis, patients with undetectable MRD had an 82% reduction in the risk of progression or death (hazard ratio, 0.18; 95% CI, 0.11 to 0.30; P The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in MM. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1527-7755 |
| العلاقة: | http://hdl.handle.net/10668/14743Test |
| DOI: | 10.1200/JCO.19.01231 |
| الإتاحة: | https://doi.org/10.1200/JCO.19.01231Test http://hdl.handle.net/10668/14743Test |
| حقوق: | open access |
| رقم الانضمام: | edsbas.BB27CB5E |
| قاعدة البيانات: | BASE |
| تدمد: | 15277755 |
|---|---|
| DOI: | 10.1200/JCO.19.01231 |